On an earnings call in February, he answered question after question about plunging demand for his company’s vaccine against ...

Merck & Co. said it expects to lose $200 million to already-announced tariffs in 2025 amid an escalating trade war between ...

Merck stock could take another hit Thursday after the company reported another quarter of light sales for its HPV vaccine, ...

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

Proquad is rarely a newsmaker from Merck’s earnings, but this time around, the U.S. has had a series of measles outbreaks.

Find insight on Merck, Sanofi and more in the latest Market Talks covering the Health Care sector.

GARDASIL 9 is a vaccine that helps protect against disease caused by the following types of Human Papillomavirus (HPV): 6, 11, 16, 18, 31, 33, 45, 52 and 58. For more information, see Section 1.

Merck maintained its 2025 full-year revenue guidance of $64.1 billion to $65.6 billion, representing 1% to 3% growth excluding foreign exchange impacts. EPS guidance was adjusted to $8.82 to $8.97, ...

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Merck & Co., Inc. ("Merck" or the "Company") (NYSE: MRK) and reminds investors of the April 14, ...

NEW YORK, NY / ACCESS Newswire / April 14, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, ...

Merck (MRK) stock trades flat as the company lowers earnings outlook amid tariff impact, even as its Q1 2025 results beat ...

SEATTLE — Since its approval by the U.S. Food and Drug Administration in 2006, the HPV vaccine has made considerable strides in preventing cervical and oropharyngeal, or throat cancers.